Localized Prostate Cancer

Uses

Comparisons

Evidence quality

Other

Highlighted claims

• Eligible participants include men with Cambridge Prognostic Groups 1-3 prostate cancer, Gleason score 3+3 or 3+4, and PSA of 20 ng/mL or lower. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
• The trial excludes patients with prior pelvic radiotherapy or active prostate cancer treatment, while active surveillance patients remain eligible. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
• For localized prostate cancer, EBRT, brachytherapy, and radical prostatectomy are available radical treatment options. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
• The article states that no level 1 evidence shows survival superiority among EBRT, brachytherapy, and radical prostatectomy for localized prostate cancer. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
• Clinical decision-making for localized prostate cancer depends heavily on toxicity and quality of life data rather than efficacy alone. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer